Abstract
Introduction: Beta interferon (IFN-β) is known as the first-line therapy in relapsing-remitting multiple
sclerosis (RRMS). Recent studies have shown different effects of IFN-β on brain-derived neurotrophic factor
(BDNF) serum levels. Given the known role of BDNF in the restoration and conservation of the nervous
system, this study was designed to investigate the possible effect of this drug through stimulating BDNF
production.
Objectives: Impressible treatments for progressive multiple sclerosis (MS) are still being sought. Individual
response to existing treatments for MS varies significantly among patients while the risk of serious adverse
events remains an issue, especially for the novel drugs.
Patients and Methods: In this clinical trial, 96 patients newly diagnosed with RRMS were studied within
three months, in 3 groups of 32 subjects. Each group received one of the foregoing drugs (Avonex, Rebif
and Betaferon). BDNF levels were compared between different groups at the end.
Results: BDNF serum concentration in all groups was significantly different (P<0.001) compared to
baseline after 3 months. And comparison between groups showed a significant difference between the
groups receiving Betaferon (IFN-β1b) (P=0.001) and Rebif (P=0.002) compared to the other groups. Avonex
compared with either control or Betaferon (IFN-β1b) and Rebif groups showed no significant difference.
Also the correlation between the mean changes in expanded disability status scale (EDSS) and BDNF was
not observed (r = -0.189, P=0.065).
Conclusions: Significant difference in BDNF levels were observed between groups.